MarginsXMarginsX
Home › Markets › Health Care › SRZN

Surrozen Inc. (SRZN)

SRZN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$32.32
+2.25% on the day
Market cap
$616.1M
Small cap
Revenue · 2025
$3.5M
-67.4% on 2024
Net income · 2025
-$242.0M
-6960.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/0001193125-26-119818-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSRZN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001824893
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.5M
Net income-$242.0M
Operating income-$42.1M
Net margin-6960.8%
Operating margin-1210.6%
Revenue growth-67.4%
Cash$89.2M
Total assets$98.7M
P/E (computed)Net income was not positive
P/S (computed)177.2×

Warning signs

Cash runway
39.4 months
$100.4M cash at September 30, 2026
Share count, 1 year
+122.4%
2025-11-05 to 2026-11-05 · +835.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$5.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$100.4M cash; operating cash flow -$7.6M a quarter.Report 2026-09-30
Shares outstanding19,061,662 (2026-11-05); 8,571,421 a year earlier; 30,575,047 three years earlier. 3y figure adjusted for split (1-for-15 overall).Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-15 on 2023-12-14Source 2023-12-14
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-08-07
AuditorErnst & Young LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $9.4M, sold $3.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$129.7M-$4.8M$100.4MNo debt tags$10.5M10-Q 2026-11-09
Q2 2026
2026-06-30
$5.0M$50.2M-$7.4M$102.0MNo debt tags$11.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$5.0M-$127.5M-$12.5M$106.9MNo debt tags$7.5M10-Q 2026-05-06
Q4 2025
2025-12-31
$528K-$183.2M-$5.8M$89.2MNo debt tags$3.5M10-K 2026-03-23
Q3 2025
2025-09-30
$983K-$71.6M-$9.0M$81.3MNo debt tags$3.6M10-Q 2026-11-09
Q2 2025
2025-06-30
$983K$39.7M-$6.1M$90.4MNo debt tags$12.6M10-Q 2026-08-06
Q1 2025
2025-03-31
$983K-$27.0M-$9.3M$101.6MNo debt tags$11.6M10-Q 2026-05-06
Q4 2024
2024-12-31
$655K-$28.0M$3.5M$34.6MNo debt tags$10.7M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-16
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-01

Source: SEC EDGAR submissions feed, 510 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month+34.5%
3 months+33.2%
Year to date+39.9%
1 year+160.8%
From 52-week high-7.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CGEMCullinan Therapeutics Inc.$9.50-7.59%$616.7M
FDMT4D Molecular Therapeutics Inc.$11.29-7.69%$636.5M
BBTXBambusa Therapeutics Inc.$15.98-0.68%$645.4M
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier